Blog
RSS FeedPosted by Michael Wonder on 29 Jun 2017
Final NICE nod for Sanofi’s Gaucher therapy
29 June 2017 - Sanofi’s Cerdelga can now be funded on the NHS in England and Wales to treat type ...
Posted by Michael Wonder on 28 Jun 2017
NICE backs Afinitor, Sutent for neuroendocrine tumours
28 June 2017 - Novartis’ Afinitor and Pfizer’s Sutent have received backing from the National Institute for Health and Care ...
Posted by Michael Wonder on 28 Jun 2017
Cancer Drugs Fund driving early access to promising new treatments
28 June 2017 - NHS patients in England are getting early access to new drugs for lung cancer and sarcoma, ...
Posted by Michael Wonder on 27 Jun 2017
NICE launches a competition for developers of health care technologies
27 June 2017 - NICE Scientific Advice has launched a competition for small or medium sized companies, charities and academic research ...
Posted by Michael Wonder on 26 Jun 2017
More people who can get the flu jab for free should be vaccinated, says NICE
26 June 2017 - NICE is calling for people who are eligible for free flu vaccination to be offered it at ...
Posted by Michael Wonder on 22 Jun 2017
NICE approves COPD treatment roflumilast for routine NHS use
22 June 2017 - Thousands of patients to benefit from roflumilast, also known as Daxas, to treat chronic obstructive pulmonary disease ...
Posted by Michael Wonder on 19 Jun 2017
New programme will assess how digital therapies can help treat anxiety and depression
19 June 2017 - NICE is to start assessing new digital therapies that will help treat more people with anxiety and ...
Posted by Michael Wonder on 16 Jun 2017
New type of treatment for Crohn’s disease is approved by NICE
16 June 2017 - Following NICE recommendations, patients with Crohn’s disease will have routine NHS access to drug ustekinumab, which offers ...
Posted by Michael Wonder on 15 Jun 2017
'Monumental U-turn' on cancer drug
15 June 2017 - A pioneering and life-extending drug repeatedly deemed too expensive will now be offered on the NHS ...
Posted by Michael Wonder on 15 Jun 2017
Kadcyla new deal for breast cancer patients given green light in final draft guidance
15 June 2017 - A new deal on the breast cancer drug Kadcyla (trastuzumab emtansine) means that it can now be ...
Posted by Michael Wonder on 14 Jun 2017
NICE publishes multiple outcomes for Adcetris
14 June 2017 - NICE has published a Final Appraisal Consultation document for patients with Hodgkin's lymphoma and an Appraisal ...
Posted by Michael Wonder on 14 Jun 2017
Why do health technology assessment coverage recommendations for the same drugs differ across settings? Applying a mixed methods framework to systematically compare orphan drug decisions in four European countries
14 June 2017 - Health technology assessment coverage recommendations differ across countries for the same drugs. Unlike previous studies, this study ...
Posted by Michael Wonder on 13 Jun 2017
Amgen’s myeloma treatment Kyprolis gains NICE approval
13 June 2017 - NICE has recommended Amgen’s multiple myeloma treatment Kyprolis, a next generation drug which has shown itself ...
Posted by Michael Wonder on 13 Jun 2017
NICE to work with partners on developing new ways to measure quality of life across health and social care
13 June 2017 - NICE is taking part in a project that will examine how quality of life measures used to ...
Posted by Michael Wonder on 13 Jun 2017
NICE publishes appraisal consultation document for inotuzumab ozogamicin
13 June 2017 - The Department of Health has asked NICE to produce guidance on the use inotuzumab ozogamicin in the ...